Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
ConclusionsOur study demonstrated the feasibility of efficiently identifying both CD4+ and CD8+ neoantigen-specific T-cells in EOC. Autologous lymphocytes genetically engineered with tumor antigen-specific TCR can be used to generate cells for use in the personalized adoptive T-cell transfer immunotherapy.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Epithelial Cancer | Genetics | Immunotherapy | Molecular Biology | Ovarian Cancer | Ovaries | Study